Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Capital Expenditures (2016 - 2025)

iBio (IBIO) has disclosed Capital Expenditures for 14 consecutive years, with $516000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 51500.0% to $516000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $563000.0, a 166.82% increase, with the full-year FY2025 number at $16000.0, down 92.38% from a year prior.
  • Capital Expenditures was $516000.0 for Q4 2025 at iBio, up from $32000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.4 million in Q2 2022 to a low of -$201000.0 in Q1 2023.
  • A 5-year average of $1.1 million and a median of $580000.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 131.21% in 2023, then soared 51500.0% in 2025.
  • iBio's Capital Expenditures stood at $2.1 million in 2021, then surged by 38.49% to $3.0 million in 2022, then plummeted by 82.87% to $506000.0 in 2023, then plummeted by 99.8% to $1000.0 in 2024, then skyrocketed by 51500.0% to $516000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Capital Expenditures are $516000.0 (Q4 2025), $32000.0 (Q3 2025), and $1000.0 (Q2 2025).